Fulvestrant

Generic Name
Fulvestrant
Brand Names
Faslodex, Fulvestrant Mylan
Drug Type
Small Molecule
Chemical Formula
C32H47F5O3S
CAS Number
129453-61-8
Unique Ingredient Identifier
22X328QOC4
Background

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...

Indication

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

First Posted Date
2022-09-26
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
95
Registration Number
NCT05554354
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 192 locations

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Phase 2
Not yet recruiting
Conditions
Advanced Breast Cancer
Interventions
Drug: Olaparib
Drug: Fulvestrant
First Posted Date
2022-09-10
Last Posted Date
2022-09-15
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
64
Registration Number
NCT05536128
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

First Posted Date
2022-09-01
Last Posted Date
2024-06-07
Lead Sponsor
University of California, Irvine
Target Recruit Count
20
Registration Number
NCT05524584
Locations
🇺🇸

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

First Posted Date
2022-08-16
Last Posted Date
2024-12-19
Lead Sponsor
Celcuity Inc
Target Recruit Count
701
Registration Number
NCT05501886
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

🇺🇸

Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A., Winter Haven, Florida, United States

🇺🇸

John D. Archbold Memorial Hospital, Thomasville, Georgia, United States

and more 214 locations

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

First Posted Date
2022-07-21
Last Posted Date
2024-12-16
Lead Sponsor
Oana Danciu
Target Recruit Count
200
Registration Number
NCT05467891
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Arizona, Phoenix, Arizona, United States

🇺🇸

Orlando Health Cancer Institute, Orlando, Florida, United States

and more 14 locations

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Phase 3
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: BPI-16350
Drug: placebo
Drug: Fulvestrant
First Posted Date
2022-06-27
Last Posted Date
2023-07-27
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
274
Registration Number
NCT05433480
Locations
🇨🇳

Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China

🇨🇳

Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong, China

🇨🇳

Inner Mongolia People's Hospital, Hohhot, Neimenggu, China

and more 61 locations

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

First Posted Date
2022-05-26
Last Posted Date
2023-10-06
Lead Sponsor
Borstkanker Onderzoek Groep
Target Recruit Count
130
Registration Number
NCT05392608
Locations
🇳🇱

Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands

🇳🇱

Noordwest Ziekenhuisgroep, Alkmaar, Netherlands

🇳🇱

Ziekenhuis Amstelland, Amstelveen, Netherlands

and more 22 locations

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

First Posted Date
2022-05-20
Last Posted Date
2024-08-22
Lead Sponsor
Tvardi Therapeutics, Incorporated
Target Recruit Count
6
Registration Number
NCT05384119
Locations
🇺🇸

Holy Cross Health Fort Lauderdale - Holy Cross Hospital, Fort Lauderdale, Florida, United States

🇺🇸

Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States

and more 3 locations

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

First Posted Date
2022-04-14
Last Posted Date
2023-09-25
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
120
Registration Number
NCT05328440
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

First Posted Date
2022-04-08
Last Posted Date
2024-04-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
18
Registration Number
NCT05319873
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy